FDA to review CRTX 080 for hyponatremia

FDA accepted for review an NDA from Cornerstone Therapeutics Inc. (NASDAQ:CRTX) for CRTX 080 to treat hyponatremia. The PDUFA date is Oct. 29. Cornerstone gained the selective vasopressin V2 receptor ...